Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (3) , 663-676
Abstract
No abstract availableKeywords
Funding Information
- Cancer Therapeutics Cooperative Research Centre
This publication has 104 references indexed in Scilit:
- The Role of Tumor Tissue Architecture in Treatment Penetration and Efficacy: An Integrative StudyFrontiers in Oncology, 2013
- The tumor microenvironment is a dominant force in multidrug resistanceDrug Resistance Updates, 2012
- Drug Resistance and Cellular Adaptation to Tumor Acidic pH MicroenvironmentMolecular Pharmaceutics, 2011
- Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast CancerCancer Research, 2011
- CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapyBritish Journal of Cancer, 2010
- Dynamic interplay between the collagen scaffold and tumor evolutionCurrent Opinion in Cell Biology, 2010
- Tumors as Organs: Complex Tissues that Interface with the Entire OrganismDevelopmental Cell, 2010
- Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 AntagonistsCancer Research, 2010
- Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1Molecular Cancer Therapeutics, 2009
- The RGD motif in fibronectin is essential for development but dispensable for fibril assemblyJournal of Cell Biology, 2007